Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Ready, A. Farago, F. Braud, A. Atmaca, M. Hellmann, J. Schneider, D. Spigel, V. Moreno, I. Chau, C. Hann, J. Eder, N. Steele, A. Pieters, J. Fairchild, S. Antonia (2018)Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14
Hiroki Tadano, T. Torigoe (2017)Immune-related adverse events of immune checkpoint inhibitors.
Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 40 2
P. Tomasini, L. Greillier, Arnaud Boyer, Arnaud Jeanson, F. Barlesi (2018)Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
Journal of thoracic disease, 10 Suppl 9
G. Lima, A. Kahn, S. Sama, J. Savage (2019)Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
Case Reports in Oncological Medicine, 2019
J. Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, S. Topalian, K. Suri, Catherine Levy, T. Allen, S. Mavroukakis, I. Lowy, D. White, S. Rosenberg (2007)Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
Journal of Immunotherapy, 30
Troy Horvat, N. Adel, T. Dang, P. Momtaz, M. Postow, M. Callahan, R. Carvajal, M. Dickson, S. D’Angelo, K. Woo, K. Panageas, J. Wolchok, P. Chapman (2015)Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 28
L. Horn, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, B. Ding, A. López-Chávez, F. Kabbinavar, W. Lin, A. Sandler, Stephen Liu (2018)First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
The New England Journal of Medicine, 379
S. Fujiwara, N. Mimura, H. Yoshimura, D. Fujimoto, Munehiro Ito, R. Mori, Jiro Ito, K. Tomii, M. Kawamoto, N. Kohara (2019)Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis
Internal Medicine, 58
Cerebrospinal f luid cytology in patients with
A. Simonaggio, J. Michot, A. Voisin, J. Pavec, M. Collins, A. Lallart, G. Cengizalp, A. Vozy, A. Laparra, A. Varga, A. Hollebecque, S. Champiat, A. Marabelle, C. Massard, O. Lambotte (2019)Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
J. Brahmer, C. Lacchetti, B. Schneider, M. Atkins, Kelly Brassil, J. Caterino, I. Chau, M. Ernstoff, Jennifer Gardner, P. Ginex, S. Hallmeyer, J. Chakrabarty, N. Leighl, J. Mammen, D. McDermott, A. Naing, L. Nastoupil, T. Phillips, Laura Porter, I. Puzanov, C. Reichner, B. Santomasso, Carole Seigel, A. Spira, M. Suarez‐Almazor, Yinghong Wang, J. Weber, J. Wolchok, John Thompson (2018)Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 17
S. Teraoka, D. Fujimoto, T. Morimoto, H. Kawachi, Munehiro Ito, Yuki Sato, K. Nagata, A. Nakagawa, K. Otsuka, K. Uehara, Y. Imai, K. Ishida, J. Fukuoka, K. Tomii (2017)Early Immune‐Related Adverse Events and Association with Outcome in Advanced Non‐Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Journal of Thoracic Oncology, 12
C. Voskens, S. Goldinger, C. Loquai, C. Robert, K. Kaehler, C. Berking, T. Bergmann, C. Bockmeyer, T. Eigentler, M. Fluck, C. Garbe, R. Gutzmer, S. Grabbe, A. Hauschild, R. Hein, G. Hundorfean, Armin Justich, U. Keller, C. Klein, C. Mateus, P. Mohr, S. Paetzold, I. Satzger, D. Schadendorf, M. Schlaeppi, G. Schuler, B. Schuler-Thurner, U. Trefzer, J. Ulrich, J. Vaubel, R. Moos, P. Weder, T. Wilhelm, D. Göppner, R. Dummer, L. Heinzerling (2013)The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
PLoS ONE, 8
L. Cordes, N. Davarpanah, L. Reoma, Billel Gasmi, M. Quezado, Omar Khan, A. Nath, A. Apolo (2019)Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
Clinical Case Reports, 8
L. Spain, Gerard Walls, Maximilian Julve, K. O’Meara, Thomas Schmid, E. Kalaitzaki, S. Turajlic, M. Gore, J. Rees, J. Larkin (2016)Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
Annals of Oncology, 28
C. Polman, P. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. Panzara, A. Sandrock (2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
The New England journal of medicine, 354 9
F. Tuon, H. Higashino, M. Lopes, M. Litvoc, A. Atomiya, L. Antonangelo, O. Leite (2010)Adenosine deaminase and tuberculous meningitis—A systematic review with meta-analysis
Scandinavian Journal of Infectious Diseases, 42
Yuki Yonenobu, M. Ishijima, K. Toyooka, H. Fujimura (2019)[A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Rinsho shinkeigaku = Clinical neurology, 59 2
M. Leitinger, M. Varosanec, S. Pikija, R. Wass, D. Bandke, S. Weis, M. Studnicka, S. Grinzinger, M. McCoy, L. Hauer, J. Sellner (2018)Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
Frontiers in Immunology, 9
T. Akaishi, K. Narikawa, Yasushi Suzuki, S. Mitsuzawa, K. Tsukita, H. Kuroda, I. Nakashima, K. Fujihara, M. Aoki (2015)Importance of the quotient of albumin, quotient of immunoglobulin G and Reibergram in inflammatory neurological disorders with disease‐specific patterns of blood–brain barrier permeability
Neurology and Clinical Neuroscience, 3
S. Waghdhare, Ashwini Kalantri, R. Joshi, S. Kalantri (2010)Accuracy of physical signs for detecting meningitis: A hospital-based diagnostic accuracy study
Clinical Neurology and Neurosurgery, 112
R. Toyozawa, N. Haratake, G. Toyokawa, Taichi Matsubara, S. Takamori, N. Miura, M. Yamaguchi, M. Takenoyama, T. Seto (2020)Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
JTO Clinical and Research Reports, 1
M. Dalakas (2018)Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
Therapeutic Advances in Neurological Disorders, 11
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma Rangwala, J. Brahmer (2016)Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 375 19
I. Bot, C. Blank, W. Boogerd, D. Brandsma (2013)Neurological immune-related adverse events of ipilimumab
Practical Neurology, 13
M. Socinski, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, C. Kelsch, Anthony Lee, S. Coleman, Y. Deng, Yijing Shen, M. Kowanetz, A. López-Chávez, A. Sandler, M. Reck (2018)Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
The New England Journal of Medicine, 378
(2019)A and Apolo AB: Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
A. Hottinger, R. Micheli, V. Guido, Alexandra Karampera, P. Hagmann, R. Pasquier (2018)Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
Neurology® Neuroimmunology & Neuroinflammation, 5
D. Ettinger, D. Wood, C. Aggarwal, D. Aisner, W. Akerley, J. Bauman, A. Bharat, D. Bruno, Joe Chang, L. Chirieac, T. D’amico, T. Dilling, M. Dobelbower, S. Gettinger, R. Govindan, M. Gubens, M. Hennon, L. Horn, R. Lackner, M. Lanuti, T. Leal, Jules Lin, B. Loo, R. Martins, G. Otterson, S. Patel, K. Reckamp, Gregory Riely, S. Schild, T. Shapiro, J. Stevenson, S. Swanson, K. Tauer, Stephen Yang, K. Gregory, M. Hughes (2019)NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 12
(1998)Cerebrospinal f luid cytology in patients with cancer: Minimizing false‐negative results
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
(2019)Pembrolizumab‐induced auto‐ immune encephalitis in a patient with advanced non‐small cell lung cancer: A case report
F. Bompaire, C. Mateus, H. Taillia, T. Greslan, M. Lahutte, M. Sallansonnet-Froment, M. Ouologuem, J. Renard, G. Gorochov, C. Robert, D. Ricard (2012)Severe meningo-radiculo-nevritis associated with ipilimumab
Investigational New Drugs, 30
Jonathan Blackmon, Toni Rn (2016)Central nervous system toxicities of anti-cancer immune checkpoint blockade
G. Thwaites, T. Hien (2005)Tuberculous meningitis: many questions, too few answers
The Lancet Neurology, 4
Dai Takamatsu, Nobuki Furubayashi, T. Negishi, Kosuke Ieiri, Tomohiro Inoue, Keiji Tsukino, Motonobu Nakamura (2019)Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
Molecular and Clinical Oncology, 11
Aseptic meningitis is a rare immune‑related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non‑specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non‑small cell lung cancer (NSCLC). The present study includes a report of such a case and a review of the related literature. A 67‑year‑old Japanese man received first‑line pembrolizumab treatment for NSCLC and subsequently developed severe nausea and vomiting. No significant findings were observed following a computed tomography (CT) scan, MRI of the brain and upper gastrointestinal tract, or upper gastrointestinal endoscopy. Cerebrospinal fluid analysis revealed lymphocyte infiltration and elevation of the IgG index, without indications of metastasis or infection, which suggested the presence of aseptic meningitis. The symptoms immediately improved following prednisolone treatment, and aseptic meningitis was diagnosed as an irAE related to pembrolizumab treatment. Given that aseptic meningitis can cause non‑specific symptoms, including headache and nausea, the possibility of an irAE should be considered in patients with non‑specific symptoms who are receiving ICIs, and a cerebrospinal fluid examination should be performed.
Molecular and Clinical Oncology – Spandidos Publications
Published: Jul 7, 2022
Access the full text.
Sign up today, get DeepDyve free for 14 days.